CINCINNATI, Nov. 2 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of J. Michael Sprafka, MPH, PhD, as Vice President, Kendle Consulting. Dr. Sprafka will provide leadership for and drive the development of integrated product development consulting services to help biopharmaceutical companies accelerate time to market and maximize the long-term commercial value of their products. His focus will be on delivery of best-in-class consulting services for customers in the areas of regulatory affairs and submissions, risk management, epidemiology, pharmacovigilance, signal detection and safety evaluations, among others. Dr. Sprafka has held senior leadership roles in the pharmaceutical and government sectors as well as academia and brings the executive level leadership and analytical expertise needed to meet increasing customer demands and heightened global regulatory requirements. He will be based out of Kendle's global headquarters in Cincinnati and will report to Melanie Bruno, PhD, MBA, Vice President, Regulatory, Site and Medical Affairs.
"I am delighted to welcome Michael to the Kendle team," said Dr. Bruno. "His extensive and diverse experience will significantly enhance our ability to deliver best-in-class regulatory consulting services and risk management capabilities to our customers across Phase I through IV clinical development and beyond. As our customers' products move through the product life cycle, Kendle's Consulting team can assist in conducting sophisticated analyses from ongoing data sources to gain a greater understanding of side effects and adverse events and best reflect the products' safety for the patient."
The addition of Dr. Sprafka strengthens Kendle Consulting, a growing area of the Company dedicated to working with biopharmaceutical companies to optimize their clinical development planning, understand and minimize risk and manage product development and monitoring throughout the product lifecycle. By combining the cumulative expertise of Kendle's broad spectrum of clinical development services, Kendle Consulting matches thought leadership with the specific needs of our customers to maximize the value of their portfolios.
Dr. Sprafka is an epidemiologist with extensive expertise in pharmacovigilance, outcomes research and pharmacoeconomics. He has more than 15 years of senior leadership experience, having served most recently as Senior Director, Pharmacovigilance, Epidemiology and Pharmacoeconomics for Procter & Gamble Pharmaceuticals. Dr. Sprafka also has served as Associate Professor of Epidemiology at the University of Minnesota and as an Epidemiologist at the Minnesota Department of Health. He holds a Bachelor of Arts in biology, a Master of Science in environmental health, a Master of Public Health in epidemiology and a Doctorate in epidemiology from the University of Minnesota.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
SOURCE Kendle International Inc.
|SOURCE Kendle International Inc.|
Copyright©2009 PR Newswire.
All rights reserved